Press Releases May 12, 2026 05:25 PM

Synaptics Announces Fiscal Fourth Quarter 2026 Investor Conference Participation

Synaptics Announces Participation in Multiple Investor Conferences in Fiscal Q4 2026

By Priya Menon
Share
Twitter Reddit Facebook LinkedIn
SYNA

Synaptics Incorporated announced that its CEO and CFO will participate and present at several prominent investor conferences during the fiscal fourth quarter of 2026, including J.P. Morgan Global Technology Conference, TD Cowen Annual Technology, Media & Telecom Conference, Mizuho Technology Conference, and Northland Growth Conference. The company highlights its leadership in AI-edge technologies and intelligent connected devices.

Synaptics Announces Fiscal Fourth Quarter 2026 Investor Conference Participation
SYNA
Summarize with
ChatGPT Perplexity Claude Grok Gemini

Key Points

  • Synaptics executives to present at four major investor conferences in Q4 2026, increasing engagement with investors.
  • Company positions itself as a leader in AI at the edge, embedded compute, wireless connectivity, and multimodal sensing solutions.
  • Synaptics emphasizes its role in enhancing digital experiences across multiple technology domains including touch, biometrics, video, and AI-driven security processing.

SAN JOSE, Calif., May 12, 2026 (GLOBE NEWSWIRE) -- Synaptics® Incorporated (Nasdaq: SYNA) today announced its participation in the following investor conferences in the fiscal fourth quarter of 2026:

  • Rahul Patel, President and Chief Executive Officer, will present at the J.P. Morgan 2026 Global Technology, Media and Communications Conference on Monday, May 18, 2026, at 6:05 AM PT. To view the webcast or access a replay, please visit J.P. Morgan 2026 Global Technology, Media and Communications Conference.
  • Ken Rizvi, Chief Financial Officer, will participate in TD Cowen 54th Annual Technology, Media & Telecom Conference on Wednesday, May 27, 2026.
  • Ken Rizvi, Chief Financial Officer, will present at the Mizuho Technology Conference 2026 on Tuesday, June 9, 2026 at 6:45 AM PT. To view the webcast or access a replay, please visit Mizuho Technology Conference 2026.
  • Ken Rizvi, Chief Financial Officer, will virtually participate in the Northland Growth Conference 2026 on Tuesday, June 23, 2026.

About Synaptics Incorporated:
Synaptics (Nasdaq: SYNA) is driving innovation in AI at the Edge, bringing AI closer to end users and transforming how we engage with intelligent connected devices, whether at home, at work, or on the move. As a go-to partner for forward-thinking product innovators, Synaptics powers the future with its cutting-edge Synaptics Astra™ AI-Native embedded compute, wireless connectivity, and multimodal sensing solutions. We’re making the digital experience smarter, faster, more intuitive, secure, and seamless. From touch, display, and biometrics to AI-driven wireless connectivity, video, vision, audio, speech, and security processing, Synaptics is a force behind the next generation of technology enhancing how we live, work, and play. 

Follow Synaptics on LinkedIn, Facebook, Instagram, and YouTube, or visit www.synaptics.com.

For further information, please contact:
Munjal Shah
Synaptics
+1-408-518-7639
munjal.shah@synaptics.com


Risks

  • Investor presentations may not yield anticipated positive investor sentiment or translate into improved stock performance.
  • Market competition in AI and connected device technologies remains intense and could impact future growth.
  • Economic or industry-specific downturns could limit demand for Synaptics’ technology solutions, affecting financial results.

More from Press Releases

Crinetics Presents Full Results From Phase 2 Trial of Atumelnant in Congenital Adrenal Hyperplasia (CAH) in Oral Presentation at ENDO 2026 Jun 14, 2026 Crinetics Presents Long Term Data at ENDO 2026 Confirming PALSONIFY™ (paltusotine) Provides Durable, Consistent Acromegaly Control Jun 14, 2026 Celldex Presents Long-Term Barzolvolimab Results Demonstrating Sustained Off-Treatment Improvement in Angioedema in Patients with CSU at the European Academy of Allergy and Clinical Immunology Annual Meeting Jun 14, 2026 Upstream Bio Presents New Responder Analyses Demonstrating Clinically Meaningful Improvements in CRSwNP in Significant Majority of Participants Treated with Verekitug in the Phase 2 VIBRANT Trial at EAACI 2026 Jun 14, 2026 Mineralys Therapeutics Presents Late-Breaking Data on Lorundrostat and Heart Failure Risk Biomarkers at The Endocrine Society Annual Meeting (ENDO 2026) Jun 14, 2026